Dual etiology vs. MetALD: how MAFLD and MASLD address liver diseases coexistence

Basit Öğe Kaydı
dc.authorid0009-0005-1472-7563
dc.authorid0000-0001-9886-0698
dc.authorid0000-0002-8618-6402
dc.authorid0000-0001-8460-1185
dc.authorid0000-0001-7634-0843
dc.authorid0009-0004-5823-6910
dc.authorid0000-0002-8909-2102
dc.contributor.authorZerehpooshnesfchi, Shadi
dc.contributor.authorLonardo, Amedeo
dc.contributor.authorFan, Jian-Gao
dc.contributor.authorElwakil, Reda
dc.contributor.authorTanwandee, Tawesak
dc.contributor.authorAltarrah, Munira
dc.contributor.authorÖrmeci, Necati
dc.contributor.authorEslam, Mohammed
dc.date.accessioned2025-05-13T18:37:43Z
dc.date.available2025-05-13T18:37:43Z
dc.date.issued2025
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractFatty liver disease associated with metabolic dysfunction has emerged as a significant global health challenge. This condition often coexists with other liver diseases, such as alcohol-related liver disease and viral hepatitis, complicating both diagnosis and management. To address the limitations of the non-alcoholic fatty liver disease (NAFLD) classification, two alternative frameworks have been proposed: metabolic dysfunction-associated fatty liver disease (MAFLD) in 2020 and metabolic dysfunction-associated steatotic liver disease (MASLD) in 2023. A key difference between these definitions is how they consider fatty liver disease in relation to the coexistence of other liver conditions. MAFLD adopts a dual etiology concept, creating a unified classification system that aligns with contemporary clinical and epidemiological needs. In contrast, MASLD introduces a new term, MetALD (metabolic and alcohol-related/associated liver disease), to describe patients who have both metabolic dysfunction and excessive alcohol intake. This review critically examines the clinical, research, and epidemiological implications of the differing approaches of MAFLD and MASLD, offering insights into their potential to enhance the understanding and management of multi-etiology liver diseases.
dc.identifier.citationZerehpooshnesfchi, S., Lonardo, A., Fan, J. G., Elwakil, R., Tanwandee, T., Altarrah, M., Örmeci, N., & Eslam, M. (2025). Dual etiology vs. MetALD: how MAFLD and MASLD address liver diseases coexistence. Metabolism and Target Organ Damage, 5(15), pp. 1-11. https://dx.doi.org/10.20517/mtod.2025.04
dc.identifier.doi10.20517/mtod.2025.04
dc.identifier.endpage11
dc.identifier.issn2769-6375
dc.identifier.issue15
dc.identifier.scopusqualityQ3
dc.identifier.startpage1
dc.identifier.urihttps://dx.doi.org/10.20517/mtod.2025.04
dc.identifier.urihttps://hdl.handle.net/20.500.13055/982
dc.identifier.volume5
dc.identifier.wosWOS:001472719200002
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynak.otherESCI - Emerging Sources Citation Index
dc.institutionauthorÖrmeci, Necati
dc.institutionauthorid0000-0002-8909-2102
dc.language.isoen
dc.publisherOAE Publishing
dc.relation.ispartofMetabolism and Target Organ Damage
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectMAFLD
dc.subjectNAFLD
dc.subjectMASLD
dc.subjectDual Etiology
dc.subjectMetALD
dc.titleDual etiology vs. MetALD: how MAFLD and MASLD address liver diseases coexistence
dc.typeReview Article
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
Ä°sim:
Tam Metin / Full Text
Boyut:
2.92 MB
Biçim:
Adobe Portable Document Format
Ä°ndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
Ä°sim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
Ä°ndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu